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Abstract Medication overuse headache (MOH) is a
severe burden to sufferers and its treatment has few evi-
dence-based indications. The aim of this study is to eval-
uate efficacy and safety of nabilone in reducing pain and
frequency of headache, the number of analgesic intake and
in increasing the quality of life on patients with long-
standing intractable MOH. Thirty MOH patients were
enrolled at the University of Modena’s Interdepartmental
Centre for Research on Headache and Drug Abuse (Italy)
in a randomized, double-blind, active-controlled, crossover
study comparing nabilone 0.5 mg/day and ibuprofen
400 mg. The patients received each treatment orally for
8 weeks (before nabilone and then ibuprofen or vice versa),
with 1 week wash-out between them. Randomization and
allocation (ratio 1:1) were carried out by an independent
pharmacy through a central computer system. Participants,
care givers, and those assessing the outcomes were blinded
to treatment sequence. Twenty-six subjects completed the
study. Improvements from baseline were observed with
both treatments. However, nabilone was more effective
than ibuprofen in reducing pain intensity and daily anal-
gesic intake (p \ 0.05); moreover, nabilone was the only
drug able to reduce the level of medication dependence
(-41 %, p \ 0.01) and to improve the quality of life
(p \ 0.05). Side effects were uncommon, mild and disap-
peared when nabilone was discontinued. This is the first
randomized controlled trial demonstrating the benefits of
nabilone on headache, analgesic consumption and the
quality of life in patients with intractable MOH. This drug
also appears to be safe and well-tolerated. Larger scale
studies are needed to confirm these preliminary findings.
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Introduction
Medication overuse headache (MOH) is a chronic head-
ache (C15 days/month) that develops from primary head-
aches (migraine, tension-type headaches). It has been
described as the result of an interaction between an over-
used therapeutic agent and a susceptible patient [1, 2].
MOH is a common problem in tertiary headache centers,
especially in patients with chronic migraine. The diagnosis
is very important because patients seldom respond to pro-
phylactic treatment, if the medication overuse for the acute
condition continues [3–5].
MOH is a considerable burden for sufferers; its patho-
physiology is unclear and its treatment has few evidence-
based indications [1, 6, 7].
It has been suggested that this condition may be medi-
ated by cognitive impulsiveness and has certain mecha-
nisms in common with addiction and substance abuse [8].
A high percentage of patients with chronic daily head-
ache with a high risk to develop MOH met the criteria for
substance abuse according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV).
They also demonstrated that the prevalence of dependence
according to DSM-IV varied with the different types of
analgesic being overused [9].
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In most cases, treatment of MOH includes an abrupt
interruption of medication overuse through appropriate
supportive care and the introduction of prophylactic treat-
ment. There is no evidence on the most efficacious way to
discontinue medication overuse. As the number of patients
with this kind of problem continues to grow, MOH has
become one of the main challenges of headache treatment
in headache clinics [10–12].
Researches and current models are based on the
assumption that it is caused by alterations in the nocicep-
tive threshold and central sensitisation in susceptible indi-
viduals [13, 14].
These processes have a number of characteristics in
common with chronic neuropathic pain or fibromyalgia,
chronic conditions for which nabilone has been tested with
encouraging results [15–17]. Increasing evidences are
available concerning the benefits of cannabinoid agents in
pain management, it should prompt to design larger and
longer-term studies on their effects in homogeneous pop-
ulations with chronic pain [18].
In one recent review of published studies on non-cancer
pain, cannabinoids appeared to have proven safety and
modest efficacy in the treatment of neuropathic pain
whereas, there are some evidences of efficacy also in
fibromyalgia and rheumatoid arthritis [19]. Other studies
gave similar results in the management of neuropathic
pain: one comparing nabilone and gabapentin used as add-
on or mono-therapy in patients with peripheral neuropathy
[20] and another comparing nabilone with dihydrocodeine
in neuropathic pain [21].
Nabilone is a synthetic cannabinoid CB1-receptor ago-
nist (licensed in Canada since 1981 for chemotherapy-
induced vomiting and nausea); it is well-tolerated and has a
good safety profile [22, 23]. Reports of its abuse are
extremely rare and the drug has been even recently sug-
gested to be a potential treatment for marijuana addiction
[24, 25].
Cannabis derivatives have been suggested for the
treatment of chronic pain conditions. Therefore, we tested
the effects of nabilone in patients suffering from intracta-
ble/refractory MOH [26]. The study was aimed to inves-
tigate the efficacy of nabilone in reducing headache days,
intensity of pain and analgesic intake in these patients.
The enrolled patients in the past performed many ther-
apeutic attempt to withdraw daily analgesic abuse, without
any clinical benefits.
It was well known by clinicians that their refractory
headache patients did not suspend their antimigraine drugs
without an alternative treatment.
Our ethic commitee did not allow to deprive patients
suffering from daily headache of analgesic drugs by using a
placebo, so we choose to treat daily attacks with a unique
drug for all patients, by using ibuprofene as rescue medi-
cation or another drug if it was ineffective.
Materials and methods
Patients
Between February 2009 and May 2010, 30 outpatients
attending the University of Modena and Reggio Emilia’s
Interdepartmental Centre for Research on Headache and
Drug Abuse (Italy) were enrolled.
Eligible patients were men and women who were not
pregnant, aged between 35 and 65 years, with daily anal-
gesic intake and who had MOH for at least 5 years. The
age of headache onset had to be under 50 years and
patients had to have already attempted detoxification at
least three times, without success.
The diagnosis was formulated according to the ICHD-II
criteria for MOH [27].
The exclusion criteria, at the screening visit, included
blood test alterations and the previous continuative use of
ibuprofen as anti-headache drug; systolic blood pressure
[160 mmHg or diastolic pressure [100 mmHg; heart rate
[100 bpm; patients with a history of drug addiction;
patients with hypersensitivity to cannabinoids; patients not
in possession of their full mental capacity or who have
been declared legally incapacitated; patients with psychotic
disorders or schizophrenia, bleeding disorders, pancreatic
diseases, stomach or duodenal disorders, liver diseases,
kidney diseases; patients treated with anticoagulants or
antiplatelet agents and pregnant or breastfeeding women.
The study protocol was approved by the Independent
Ethics Committee of Modena. The study was conducted in
compliance with the provisions set forth in the Declaration
of Helsinki (last version) and EU standards of Good
Clinical Practice. All patients gave their written informed
consent.
Study design
A not-for-profit, independent, randomized, double-blind,
active-controlled, crossover study (using a two period
design, allocation ratio 1:1) was conducted on 30 outpa-
tients attending the University of Modena’s Interdepart-
mental Centre for Research on Headache and Drug Abuse
(Italy), where study visits took place, clinical data were
collected and drugs were dispensed.
For treating headache attacks we decided to use a drug
not overused by any patient, as safe as possible and that
was not evaluable as potential prophylaptic treatment for
headache.
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Patients were randomly assigned to receive both
treatments at home: one period with nabilone and one
period with ibuprofen, in a blinded sequence. The drugs
were taken orally every day and each treatment period
lasted 8 weeks. Neither the doctors and nurses nor study
patients knew which treatment sequence had been
allocated.
Sixty doses of nabilone (0.5 mg) and 60 doses of ibu-
profen (400 mg) were prepared for each patient by an
independent pharmacy, as identical white capsules and
randomized in two containers, named Drug A and Drug B.
The pairs of containers were consecutively numbered for
each subject according to the randomization schedule,
generated by a computer. Each patient was assigned an
order number and received the capsules in the corre-
sponding pair of containers.
The study lasted 20 weeks and the protocol consisted
of six visits. V0: screening visit; V1: enrolment visit
(baseline); V2: dispensing the Drug A container (60
capsules) and start of the first period of treatment (after
1 week from discontinuation of the overused medica-
tions at the day hospital of the headache centre); V3:
crossover visit, dispensing Drug B container (60 cap-
sules) and start of the second period of treatment (after
1 week of washout); V4: end of treatment visit; V5:
follow-up visit, 2 weeks after discontinuation of treat-
ment (Fig. 1).
At each scheduled visit (V1–V5), subjects enrolled in
the study, who had given their written informed consent,
were examined (particularly as regards the evaluation of
headache characteristics) and their vital signs and details of
any concomitant medication were recorded. Specifically, a
detailed medication history was recorded, including
prior prophylactic and symptomatic treatments (the type of
drugs used, length of use and any adverse event requiring
discontinuation).
In addition, at each visit, the headache diary was
reviewed and self-assessment tests were administered to
patients.
Outcome measures
The main aim of the study was to evaluate the efficacy and
tolerability of nabilone (0.5 mg/day) for the treatment of
MOH.
Primary outcomes to assess the efficacy of treatment were
the reduction of the headache frequency, the duration and
intensity of headache pain and the amount of daily analgesic
consumption. Headache frequency was evaluated using the
Headache Index (HI), i.e. the number of headache days per
month. The mean duration of pain was evaluated calculating
the hours of pain per day (reported in the headache diary); the
mean intensity of pain was recorded using the 10 cm Visual
Analogue Scale (VAS), which was administered at each visit.
In addition, the reduction in the number of analgesics or
antimigraine drugs taken during the observation period, was
considered as an indirect efficacy parameter and it was
measured as daily analgesic intake (DAI).
The secondary outcome measures were the improvement
in the quality of life and mental health, assessed through the
administered: HIT-6TM (Headache Impact Test), SF-36
questionnaire and the Zung Depression and Anxiety Scales.
We also recorded the level of dependence using the Leeds
Dependence Questionnaire (LDQ) appropriately modified for
headache and consumption of analgesics [28]. This scale
does not indicate whether consumption is of a risky level and
it was used to monitor changes during the various phases of
the study (0 = no dependence; 1–10 = low to moderate
dependence; 11–20 = moderate to high dependence; 21–30 =
high dependence) [29].
Safety
The safety and tolerability of the drugs were evaluated at
V2, V3, V4 and V5. The safety was assessed by measuring
the blood pressure, heart rate and through a medical
examination during which the patients were asked about
any adverse events during the study period. Moreover, by
administration of a diary in which patients were asked to
record any adverse events occurring during the treatments
and the follow-up period.
Statistical analysis
The continuous variables were expressed as mean ±
standard deviation. To compare all the clinical outcomes
(primary and secondary) between the different treatment
periods, we used the t test for paired data. To compare
clinical outcomes between single and multi drug overuser,
we used t test for unpaired data. All the tests were two-
tailed and p \ 0.05 was considered statistically significant.
STATA software (version 10, StataCorp LP, TX, USA)
was used for the statistical analyses.
Fig. 1 Study design
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Study oversight
The corresponding author prepared the first draft of the
manuscript and decided to submit the manuscript for
publication, after which all the authors worked together to
edit the subsequent drafts. All the authors examined and
approved the final draft of the manuscript and assumed
responsibility for the accuracy and completeness of the
data and data analysis and the consistency between the
study and the trial protocol.
Results
Thirty MOH patients aged between 35 and 65 years
(mean ± SD = 52.7 ± 9.6), were recruited after the
screening visit and allocated according to the randomiza-
tion schedule; 20 females (66.6 % aged 53.3 ± 9.1 years)
and 10 males (33.3 % aged 49.7 ± 11.8 years). All sub-
jects had suffered from chronic headache for at last 3 years.
Mean duration was similar for both men and women:
10.3 ± 10.7 and 13.6 ± 10.8 years, respectively. All sub-
jects had a current history of overuse of analgesics or an-
timigraine drugs; for this study we took into account drugs
overused for the 3 months prior to the start of the trial.
Medication overused involved triptans in 53 % of the
subjects enrolled, combination medications (CM) in 37 %
and NSAIDs in 30 %.
Twenty-six subjects completed the study and four
dropped out after randomization and allocation. In two
cases patients stopped the treatment due to the side effects
of the medication (one for nabilone and one for ibuprofen).
Other two subjects interrupted the study spontaneously:
one subject simply changed his mind after completing the
initial washout period, without starting the trial treatment
(dropout at V2), and the other one dropped out due to lack
of efficacy during the first treatment period (at V3).
At baseline, on average, the patients enrolled had a high
analgesic intake (DAI 2.1 ± 1.4) and a high level of drug
dependence (15.9 ± 6.3), according to the LDQ score
(Fig. 2).
The highest DAI values were observed in those subjects
in whom CM (2.8 ± 1.67) was the main overused drug,
followed by NSAIDs (1.7 ± 1.03) and then triptans (1.6 ±
0.69), without statistical significant differences between
the drugs.
The efficacy data for the main indicators considered are
given in Table 1 and the quality of life data is summarised
in Table 2.
Both drugs showed improvements compared to baseline
in all the primary endpoints, however, certain differences
were observed between the two treatments. Nabilone was
directly superior to ibuprofen in reducing DAI, pain
intensity and the level of dependence (Table 1; Fig. 2). In
addition, the quality of life indicators changed with nabi-
lone, but not with ibuprofen: a significant improvement
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Fig. 2 DAI during the trial
Table 1 Efficacy data of primary outcomes
Basal Nabilone Ibuprofen Follow-up
n 30 26 26 26
HI 0.95 ± 0.1 0.72 ± 0.3** 0.78 ± 0.3** 0.77 ± 0.3*
DAI 2.1 ± 1.4 0.89 ± 0.5**, 1.34 ± 0.9** 1.44 ± 1.1**
VAS 7.9 ± 1.6 5.7 ± 1.9**, 6.6 ± 2.2** 6.2 ± 2.4**
LP (h) 16.1 ± 7.1 8.7 ± 6.6** 10.4 ± 7.3* 11.1 ± 7.6**
LDQ 15.9 ± 6.3 9.2 ± 5.9**, 13.8 ± 6.6 11.9 ± 6.1*
PFD 2.1 ± 0.2 8.1 ± 9.3* 6.6 ± 6.3* 6.9 ± 6.3*
Both drugs showed improvements in all outcomes, but nabilone was
always more effective than ibuprofen, with statistically significant
differences in DAI, VAS and LDQ values
HI Headache Index, DAI daily analgesic intake, VAS Visual Analogue
Scale, LP lasting of pain, LDQ Leeds Dependence Questionnaire,
PFD pain free days/month
Paired t test * p \ 0.05 and ** p \ 0.01 versus basal;  p \ 0.05
versus ibuprofen
Table 2 Evaluation of the quality of life
Basal Nabilone Ibuprofen Follow-up
HIT-6 67.3 ± 5.2 62.8 ± 8* 64.9 ± 9.5 63 ± 8.7
SF-36
mental
35.4 ± 11.7 40.2 ± 10.4* 38.8 ± 11.1 40.6 ± 15.9
SF-36
physical
33.1 ± 8 39.5 ± 7.7* 37.2 ± 8.1 38 ± 9.8
ZAS 41.3 ± 7.8 37.9 ± 11.5 39.2 ± 9.5 40.5 ± 11.7
ZDS 44.1 ± 9.3 41.3 ± 11.1 41.3 ± 9.2 43.2 ± 12.7
The improvements recorded in quality of life scales occurred only
with nabilone
HIT-6TM Headache Impact Test, SF-36 Short Form Health Survey,
ZAS Zung Anxiety Scale, ZDS Zung Depression Scale
Paired t test * p \ 0.05 versus basal
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was seen in SF-36 Scale (for both physical and mental
components) and HIT-6TM Scales (Table 2).
A deeper analysis showed that the improvements com-
pared to baseline recorded with ibuprofen only occurred in
subjects taking ibuprofen during the first period of treat-
ment (i.e. DRUG A), but not in subjects taking ibuprofen
during the second period of treatment (i.e. DRUG B). The
improvements recorded with nabilone compared to base-
line, instead, took place regardless of when the therapy was
received.
As far as the post-treatment results are concerned
(recorded at the follow-up visit, 2 weeks after discontinu-
ation of the DRUG B), the improvements compared to
baseline persisted. However, these improvements depended
on the sequence of the pharmacological treatments since,
compared to baseline, only patients receiving nabilone
during the last 2 months maintained a significant prolonged
improvement (carry-over effect), in the HI, DAI, VAS and
HIT-6TM indices. The subjects who received ibuprofen
during the last 2 months of treatment, on the other hand,
did not show any improvement compared to baseline. The
post-treatment results are given in Table 3.
With regard to the habits of taking the overused medi-
cations, there were two types of patients: those who were
overusing just one medication, who were termed single
drug overusers (SDO 15 subjects) and those who were
overusing two or more different medications, who were
termed multi drug overusers (MDO 15 subjects).
The MDO group had far higher DAI values than the
SDO group: 2.61 ± 1.6 versus 1.60 ± 0.79, respectively
(p \ 0.05). This difference in the consumption rate
between the two groups of overusers persisted at each visit.
We always observed higher DAI values in the MDO group
(p \ 0.05), however, this did not occur during the period of
treatment with nabilone. During the treatment with nabi-
lone, but not with ibuprofen, the DAI dropped regardless of
the type of overuse, for both SDO and MDO patients
(Fig. 3).
Safety
All the adverse events (Table 4) were of a mild intensity
and disappeared after discontinuation of the medication or
spontaneously after a few days of treatment. The main
AEs, which caused the withdrawal of two patients, were of
a moderate intensity in both cases. One woman reported
mild gastric discomfort during treatment with ibuprofen,
whereas during treatment with nabilone, one man com-
plained of mild cognitive disorders (loss of concentration
and memory), symptoms that disappeared within a month
after withdrawal. Throughout the entire study, there were
no changes in blood pressure, heart rate or body weight.
Discussion
Cannabinoids, like many analgesics and recreational drugs,
act on the brain’s reward pathways. Cannabinoid-1 recep-
tors (CB1R) are co-localized with the opioid receptors on
the dopaminergic cells of the nucleus accumbens, probably
the most important structure in human reward pathways,
which partly overlaps the antinociceptive pathways [30–
32].
The oral administration of cannabinoid drugs shows
poorer bioavailability than when these drugs are adminis-
tered by inhalation. An oromucosal spray of THC was one
way of releasing active principle into the central nervous
system, however, the rapid administration of cannabinoid
drugs had different effects to those observed with slow
absorption: the reward system is activated by a rapid rise in
cannabinoids concentration, such as to obtain a significant
euphoric effect (a ‘high’), the main cause of dependence.
The oral cannabinoids administration, on the other hand,
avoids concentration peaks and with chronic administra-
tion, the individual differences in bioavailability are over-
come [23, 33]. The use of nabilone, a cannabinoid1-
receptor agonist, would therefore appear reasonable in the
Table 3 Post-treatment outcomes
Ibuprofen Nabilone
Basal Follow-up Basal Follow-up
HI 0.97 ± 0.1 0.86 ± 0.3 0.93 ± 0.1 0.65 ± 0.4*
DAI 2.02 ± 1.2 1.8 ± 1.3 2.34 ± 1.6 0.99 ± 0.8*
VAS 8 ± 1.6 6.75 ± 2.4 7.8 ± 1.7 5.55 ± 2.5**
HIT-6TM 68.4 ± 5.7 63.1 ± 11.9 66.7 ± 4.8 64 ± 6.8*
The post-treatment improvements occurred only in patients who
received nabilone during the second period of treatment
HI Headache Index, DAI daily analgesic intake, VAS Visual Analogue
Scale; HIT-6TM Headache Impact Test
Paired t test * p \ 0.05 and ** p \ 0.01 versus basal
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Fig. 3 Time-course DAI in multidrug overusers versus single drug
overusers
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treatment of MOH for which central mechanisms are
hypothesised in the maintenance of chronic head pain due
to medication overuse.
We studied a group of patients who had been suffering
from MOH for a long time (on average more than 12 years)
and who had used various pharmacological and other
approaches, without achieving any positive results.
When resistant to conventional medical treatment and
prophylactic medication this condition is known as
refractory chronic migraine [34].
Our patients presented almost daily headache (HI =
0.95 ± 0.1), with really high DAI values at baseline
(2.1 ± 1.4). In these patients, the main unresolved problem
is the excessive use of drugs for the acute treatment and the
overall deterioration experienced in their quality of life, so
the headache symptoms should be considered as part of the
issue as a whole [2, 6, 7].
Nabilone seemed more helpful in reducing the intensity
of pain than the frequency. The mean intensity of pain
(measured using the VAS) dropped significantly (p \ 0.01)
both with nabilone (-27.9 %) and with ibuprofen
(-17.8 %), with a difference between the two treatments in
favour of nabilone (p \ 0.05).
The frequency of headache had only very small improve-
ments, probably due to the short period of treatment.
Nabilone showed a remarkable improvement in drug
consumption. So, the most important effect recorded
with nabilone was especially in reducing drugs overuse,
with DAI values more than halved the baseline. DAI
dropped during both treatments: -36.2 % with ibuprofen
(p \ 0.01) and -57.7 % with nabilone (p \ 0.01), which
was significantly superior to ibuprofen, in reducing analgesic
intake (DAI = 0.89 ± 0.5 and 1.34 ± 0.9, respectively,
p \ 0.05). In addition, a deeper analyses showed significant
differences between the DAI in single drug overusers and in
multi drug overusers: during treatment with nabilone both
SDO and MDO improved in a similar way, however, this was
not so for the period of treatment with ibuprofen as MDO
patients maintained higher overuse than SDO (Fig. 3). This
result agrees with the clinical observation that multi drug
overusers experience greater difficulties in reducing DAI and
are less sensitive to treatments. Nabilone seems able to help
patients with multi drug overuse [12].
This great reduction in DAI recorded with nabilone is
also concordant with the changes in the consumption habits
of drugs, recorded by the Leeds Dependence Question-
naire. The LDQ score showed a high baseline value, of
about 16 points and was similar to the score obtained in a
previous study on patients suffering from chronic daily
headaches [28]. The questionnaire indicated a significant
reduction in the level of dependency compared to baseline
during treatment with nabilone (-42.2 %; p \ 0.01), but
not with ibuprofen (Table 1).
A reduced use of medication implies a reduced effect of
headache pain on the quality of life. The slight improve-
ments in the quality of life (in HIT-6TM and SF-36), were
recorded only with nabilone and not with ibuprofen
(Table 3); the small degree of these improvements is
probably in relation to the short duration of treatment.
Nabilone’s ability to reduce DAI in both types of ove-
rusers (SDO and MDO) associated with a reduction in the
LDQ score suggests that nabilone could affect the degree
of dependence in both of these conditions.
The main limits of our research were the small sample
size and the short duration of the study. However, our
results were obtained in a selected chronic headache pop-
ulation considered a representative sample of the most
severe MOH patients who failed to respond to all available
pharmacological treatments.
Conclusions
To conclude, nabilone, a cannabinoid 1-receptor agonist, at
daily doses, would appear beneficial for patients suffering
from MOH, primarily in reducing the intensity of pain and
the analgesic intake and appeared to be significantly more
efficacious than ibuprofen. In addition, nabilone alone
reduced the level of drug dependence (LDQ -41 %,
p \ 0.01) and improved the quality of life scales
(p \ 0.05). The number of days with headache was not
significantly reduced in the same way as the other indica-
tors, probably due to the short duration of the study. Side
effects were infrequent, of mild intensity and disappeared
after discontinuation of the treatment. This randomized,
controlled trial evaluated the benefits of nabilone on
Table 4 Adverse Events
Nabilone Ibuprofen
Dizziness 2 –
Sleep disorders – 1
Decreased appetite 1 2
Vomiting 2 –
Nausea 1 2
Drowsiness – –
Asthenia 2 –
Epigastric discomfort 1 2
Dry mouth 2
Loss of attention – 1
Memory impairment – –
TOTAL 11 8
Adverse events were mild and disappeared after few days of treatment
or after drug discontinuation
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headache, analgesic consumption and the improvements in
quality of life in patients with MOH. Nabilone would also
appear to be safe. Larger-Scale studies are required to
confirm the effectiveness and safety of nabilone [1, 7].
What is already known about this study: although can-
nabinoids have been used as painkillers for centuries, there
is little evidence-based information available on their use.
At low doses, they have few psychotropic side effects,
which disappear rapidly in patients with chronic headache.
What this study adds: nabilone, a synthetic oral can-
nabinoid, is efficacious in the treatment of medication
overuse headache.
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